These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21913053)

  • 1. Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
    Rekić D; Clewe O; Röshammar D; Flamholc L; Sönnerborg A; Ormaasen V; Gisslén M; Abelö A; Ashton M
    AAPS J; 2011 Dec; 13(4):598-605. PubMed ID: 21913053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
    Rekić D; Röshammar D; Bergstrand M; Tarning J; Calcagno A; D'Avolio A; Ormaasen V; Vigan M; Barrail-Tran A; Ashton M; Gisslén M; Äbelö A
    AAPS J; 2013 Apr; 15(2):308-15. PubMed ID: 23224752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
    Karlström O; Josephson F; Sönnerborg A
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
    Petersen K; Riddle MS; Jones LE; Furtek KJ; Christensen AR; Tasker SA; Hale BR
    AIDS; 2005 Oct; 19(15):1700-2. PubMed ID: 16184044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
    Johnson DH; Venuto C; Ritchie MD; Morse GD; Daar ES; McLaren PJ; Haas DW
    Pharmacogenet Genomics; 2014 Apr; 24(4):195-203. PubMed ID: 24557078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.
    Barrail-Tran A; Mentré F; Cosson C; Piketty C; Chazallon C; Gérard L; Girard PM; Taburet AM
    Antimicrob Agents Chemother; 2010 Feb; 54(2):614-9. PubMed ID: 19995932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
    Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
    J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
    DiCenzo R; Peterson DR; Cruttenden K; Mariuz P; Rezk NL; Hochreiter J; Gelbard H; Schifitto G
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3035-9. PubMed ID: 18573930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
    Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
    Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of atazanavir: a novel HIV protease inhibitor.
    Fuster D; Clotet B
    Expert Opin Pharmacother; 2005 Aug; 6(9):1565-72. PubMed ID: 16086644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug profile: atazanavir (Reyataz, ATV).
    Pham PA
    Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.
    McCance-Katz EF; Moody DE; Morse GD; Ma Q; DiFrancesco R; Friedland G; Pade P; Rainey PM
    Drug Alcohol Depend; 2007 Dec; 91(2-3):269-78. PubMed ID: 17643869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atazanavir: clinical use.
    Bartlett JG
    Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
    [No Abstract]   [Full Text] [Related]  

  • 19. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
    Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
    J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.